One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
HOOKIPA Pharma  logo
HOOKIPA Pharma HOOK
report update icon

Quarterly report 2025-Q1
added 05-16-2026

HOOKIPA Pharma Cash Flow 2024-2011 | HOOK

Brief cash flow overview of HOOKIPA Pharma

The review uses the five latest available annual reports between 2020 and 2024.

The latest year produced an operating outflow of -$77 million. A return to positive cash generation is important.

Only 0 of five observations were above zero. The business relies heavily on individual strong periods.

Cash flow takeaway

HOOKIPA Pharma 's cash flows remain vulnerable. Negative or unstable generation materially reduces financial flexibility.

Annual Cash Flow HOOKIPA Pharma

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-77 M -57.5 M -20 M -66 M -39.3 M -41.7 M -15 M -11.9 M - - - - - -

Depreciation & Amortization

2.75 M 3.55 M 3.6 M 4.64 M 4.15 M 3.07 M 640 K 398 K - - - - - -

Accounts Payables

8.69 M 12.5 M 5.49 M 8.76 M 8.01 M 944 K - - - - - - - -

Accounts Receivables

290 K 511 K 6.53 M 6.9 M 5.54 M 1.54 M - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow HOOKIPA Pharma

2025-Q1 2024-Q3 2024-Q2 2024-Q1 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

52 K - - -24.2 M - - -2.85 M - -33.1 M -16.6 M 1.73 M - -52.8 M -35.1 M -14.4 M - -28 M -17.7 M -7.13 M - -32.9 M -23.5 M -12.1 M - -8.62 M -1.46 M -4.97 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

389 K - - 640 K - - 921 K - 2.7 M 1.94 M 1.08 M - 3.41 M 2.32 M 1.1 M - 3.04 M 1.87 M 903 K - 1.04 M 670 K 297 K - 462 K 291 K 140 K - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

3.67 M 8.96 M 11.3 M - 8.93 M 11.6 M 7.08 M 5.49 M 7.82 M 5.64 M 6.71 M 8.76 M 10.1 M 10.9 M 8.05 M 8.01 M 8.01 M 8.01 M 8.01 M 944 K 944 K 944 K 944 K 3.66 M 3.66 M 3.66 M 3.66 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

545 K 324 K 82 K - 675 K 255 K 501 K 6.53 M 743 K 1.19 M 703 K 6.9 M 2.52 M 4.92 M 4.28 M 5.54 M 5.54 M 5.54 M 5.54 M 1.54 M 1.54 M 1.54 M 1.54 M 4.92 M 4.92 M 4.92 M 4.92 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company HOOKIPA Pharma , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 11.84 0.87 % $ 1.06 B usaUSA
Seagen Seagen
SGEN
- - $ 42.2 B usaUSA
Codexis Codexis
CDXS
$ 1.24 5.43 % $ 108 M usaUSA
Cullinan Management Cullinan Management
CGEM
$ 12.93 2.64 % $ 779 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.96 4.0 % $ 183 M israelIsrael
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 1.14 0.84 % $ 2.97 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 11.32 0.17 % $ 4.7 B irlandaIrlanda
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.02 0.49 % $ 11.5 M usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 3.28 3.25 % $ 402 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 23.19 0.04 % $ 734 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 4.52 4.39 % $ 60.2 M usaUSA
Curis Curis
CRIS
$ 0.41 1.4 % $ 5.4 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 9.52 5.01 % $ 752 M usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Histogen Histogen
HSTO
- 31.6 % $ 2.12 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 24.02 0.39 % $ 3.64 B usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 17.61 2.63 % $ 3.04 B usaUSA
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 6.38 0.79 % $ 278 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Precision BioSciences Precision BioSciences
DTIL
$ 5.77 2.32 % $ 74 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.35 7.49 % $ 209 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
$ 31.32 4.36 % $ 1.82 B usaUSA
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
$ 11.1 2.59 % $ 237 K usaUSA
Exelixis Exelixis
EXEL
$ 62.23 0.06 % $ 16.9 B usaUSA
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
$ 2.99 4.32 % $ 219 K usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.17 1.53 % $ 275 K usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 0.67 0.14 % $ 172 M usaUSA
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
$ 49.51 1.0 % $ 201 B britainBritain
GT Biopharma GT Biopharma
GTBP
$ 7.03 18.52 % $ 38.8 M usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.36 4.01 % $ 60 M usaUSA
Johnson & Johnson Johnson & Johnson
JNJ
$ 255.56 0.86 % $ 615 B usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 8.18 19.02 % $ 551 B britainBritain
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 28.82 10.19 % $ 3.67 B usaUSA
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
$ 0.7 0.62 % $ 42 M usaUSA
Kura Oncology Kura Oncology
KURA
$ 9.08 0.94 % $ 796 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
- -3.69 % $ 12.4 M usaUSA
Cyclerion Therapeutics Cyclerion Therapeutics
CYCN
$ 34.99 3.77 % $ 147 M usaUSA
Alector Alector
ALEC
$ 1.84 6.02 % $ 190 M usaUSA
ObsEva SA ObsEva SA
OBSV
- -15.52 % $ 10.5 M schweizSchweiz
Kronos Bio Kronos Bio
KRON
- 1.49 % $ 50.8 M usaUSA
Landos Biopharma Landos Biopharma
LABP
- 0.58 % $ 144 M usaUSA